Sanem Nalbantgil

Sanem Nalbantgil

Auto-generated profile, based on publicly available information

Sanem Nalbantgil

Department of Cardiology, Faculty of Medicine, Ege University, İzmir, Türkiye

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2022 in Balkan Medical Journal
Verified
Journal Article
Open access
YÇYüksel Çavuşoğlu
Yüksel Çavuşoğlu
HAHakan Altay
Hakan Altay
DADursun Aras
Dursun Aras
ACAhmet Celik
Ahmet Celik
FEFatih Sinan Ertaş
Fatih Sinan Ertaş
MYMehmet Birhan Yilmaz
Mehmet Birhan Yilmaz
Heart failure (HF) is considered a significant public health issue with a substantial and growing epidemiologic and economic burden in relation to longer life expectancy and aging global population. To determine cost-of-disease of heart failure (HF) in Turkey from the payer perspective. Cross-sectional cost of disease study. In this cost-of-disease study, annual direct and indirect costs of management of HF were determined based on epidemiological, clinical and lost productivity inputs provided by a Delphi panel consisted of 11 experts in HF with respect to ejection fraction (EF) status (HF patients with reduced EF (HFrEF), mid-range EF (HFmrEF) and preserved EF (HFpEF)) and New York Heart Association (NYHA) classification. Direct medical costs included cost items on outpatient management, inpatient management, medications, and non-pharmaceutical treatments. Indirect cost was calculated based on the lost productivity due to absenteeism and presenteeism. 51.4%, 19.5%, and 29.1% of the patients were estimated to be HFrEF, HFmrEF, and HFpEF patients, respectively. The total annual direct medical cost per patient was $887 and non-pharmaceutical treatments ($373, 42.1%) were the major direct cost driver. Since an estimated nationwide number of HF patients is 1,128,000 in 2021, the total annual national economic burden of HF is estimated to be $1 billion in 2021. The direct medical cost was higher in patients with HFrEF than in those with HFmrEF or HFpEF ($1,147 vs. $555 and $649, respectively). Average indirect cost per patient was calculated to be $3,386 and was similar across HFrEF, HFmrEF and HFpEF groups, but increased with advanced NYHA stage. Our findings confirm the substantial economic burden of HF in terms of both direct and indirect costs and indicate that the non-pharmaceutical cost is the major direct medical cost driver in HF management, regardless of the EF status of HF patients.

1 January 2023 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
ZDZekeriya Duzgun
Zekeriya Duzgun
MKMeral Kayikcioglu
Meral Kayikcioglu
CACagdas AKTAN
Cagdas AKTAN
BBBuşra Bara
Buşra Bara
FEFatma Zuhal Eroğlu
Fatma Zuhal Eroğlu
AVAslı Tetik Vardarlı
Aslı Tetik Vardarlı
Background/aim: Pulmonary arterial hypertension (PAH) is characterized by maladaptation of pulmonary vasculature which is leading to right ventricular hypertrophy and heart failure. miRNAs play a crucial role in the regulation of many diseases such as viral infection, cancer, cardiovascular diseases, and pulmonary hypertension (PH). In this study, we aimed to investigate the expression pattern of eight human plasma miRNAs (hsa-miR-21-3p, hsa-miR-143- 3p, hsa-miR-138-5p, hsa-miR-145-3p, hsa-miR-190a, hsa-miR-204-3p, hsamiR-206, hsa-miR-210-3p) in mild-to-severe PH patients and healthy controls. Materials and methods: miRNAs were extracted from the peripheral plasma of the PH patients (n: 44) and healthy individuals (n: 30) by using the miRNA Isolation Kit. cDNA was synthesized using All in-One First strand cDNA Synthesis Kit. Expression of the human plasma hsa-miR- 21-3p, hsa-miR-143-3p, hsa-miR-138-5p, hsa-miR-145-3p, hsa-miR-190a, hsa-miR-204- 3p, hsa-miR-206, hsa-miR210-3p, and miRNAs were analyzed by qRT-PCR. Results: According to our results, in PH patients hsa-miR-21-3p and hsa-miR-143-3p expression levels were decreased by 4.7 and 2.3 times, respectively. No significant changes were detected in hsa-miR-138-5p, hsa-miR-145-3p, hsa-miR-190a, hsa-miR-204-3p, hsamiR-206, and hsa-miR-210-3p expression levels between PH and control groups. In addition, considering the severity of the disease, it was observed that the decrease in miR-138, miR-143, miR-145, miR-190, mir-204, mir-206 and miR-208 expressions was significant in patients with severe PH. Conclusion: In the early diagnosis of PAH, hsa-miR-21-3p and especially hsa-miR-143-3p in peripheral plasma can be considered as potential biomarkers.

15 November 2018 in Turkish Journal of Gastroenterology
Verified
Journal Article
Closed access
MZMurat Zeytunlu
Murat Zeytunlu
AUAlper Uguz
Alper Uguz
ÖÜÖmer Ünalp
Ömer Ünalp
OEOrkan Ergün
Orkan Ergün
ZKZeki Karasu
Zeki Karasu
NANurşen Altuğ
Nurşen Altuğ
Background/Aims: Liver transplantation (LT) is now the standard of care for most end-stage liver diseases. Over the next 30 years, advances in medicine and technology will greatly improve the survival rates of patients after this procedure. The aim of the present study was to analyze retrospectively the results of 1001 patients withLT. Materials and Methods: Medical reports of 989 patients were analyzed retrospectively. Data were obtained from the patient’s data chart. Descriptive statistics were used to describe continuous variables (mean, median, and standard deviation). Results: A total of 1001 LTs for 989 recipients were performed at Ege University Organ Transplantation and Research Center between 1994 and 2017. Therewere 639 male and 350 female recipients. Among 1001 LTs, there were 438 deceased donors and 563 living donors. The age interval of the patients was 4 months to 71 years old. The median Model for End-Stage Liver Disease score was 20. There were 12 deceased liver donors using the split method. There were 12 cases subject to retransplantation. In living donor LT grafts, 423 right lobes, 46 left lobes, and 94 left lateral sectors were used. In the first monitoring,the total annual mortality rate was 130 cases (13%). The mortality rate in retransplantation was found to be 66%. A 1-year survival rate of 87% was generally established. Conclusion: LThas been improving consistently over the last two decades. Ege University is one of the biggest liver transplant centers in Turkey for both technical and educational perspective. Cite this article as: Zeytunlu M, Uğuz A, Ünalp Ö, et al. Results of 1001 liver transplantations in 23 years: Ege University experience. Turk J Gastroenterol 2018; 29: 664-8.

7 September 2015 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
ESEvrim Simsek
Evrim Simsek
SNSanem Nalbantgil
Sanem Nalbantgil
NCNaim Ceylan
Naim Ceylan
MZMehdi Zoghi
Mehdi Zoghi
HKHatice Soner Kemal
Hatice Soner Kemal
MOMustafa Ozbaran
Mustafa Ozbaran
Anadolu Kardiyoloji Dergisi, Anadolu Kardiyol Derg, The Anatolian Journal of Cardiology, Anatol J Cardiol, Cardiology, Cardiovascular Medicine, Surgery, Pediatric Cardiology, Angiology

27 October 1999 in Annals of Noninvasive Electrocardiology
Verified
Journal Article
Closed access
PDF file
SNSanem Nalbantgil
Sanem Nalbantgil
HYHasan Yılmaz
Hasan Yılmaz
CGCemil Gurgun
Cemil Gurgun
BGBulent Gurcay
Bulent Gurcay
MZMehdi Zoghi
Mehdi Zoghi
RORemzi Onder
Remzi Onder